Cargando…

An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination

Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Binjawadagi, Basavaraj, Dwivedi, Varun, Manickam, Cordelia, Ouyang, Kang, Torrelles, Jordi B, Renukaradhya, Gourapura J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969340/
https://www.ncbi.nlm.nih.gov/pubmed/24711701
http://dx.doi.org/10.2147/IJN.S59924
_version_ 1782309258567614464
author Binjawadagi, Basavaraj
Dwivedi, Varun
Manickam, Cordelia
Ouyang, Kang
Torrelles, Jordi B
Renukaradhya, Gourapura J
author_facet Binjawadagi, Basavaraj
Dwivedi, Varun
Manickam, Cordelia
Ouyang, Kang
Torrelles, Jordi B
Renukaradhya, Gourapura J
author_sort Binjawadagi, Basavaraj
collection PubMed
description Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and reinfections; moreover, safety of the live virus vaccines is questionable. Though poorly immunogenic, inactivated PRRSV vaccine is safe. The PRRSV infects primarily the lung macrophages. Therefore, we attempted to strengthen the immunogenicity of inactivated/killed PRRSV vaccine antigens (KAg), especially in the pig respiratory system, through: 1) entrapping the KAg in biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP-KAg); 2) coupling the NP-KAg with a potent mucosal adjuvant, whole cell lysate of Mycobacterium tuberculosis (M. tb WCL); and 3) delivering the vaccine formulation twice intranasally to growing pigs. We have previously shown that a single dose of NP-KAg partially cleared the challenged heterologous PRRSV. Recently, we reported that NP-KAg coupled with unentrapped M. tb WCL significantly cleared the viremia of challenged heterologous PRRSV. Since PRRSV is primarily a lung disease, our goal in this study was to investigate lung viral load and various immune correlates of protection at the lung mucosal surfaces and its parenchyma in vaccinated heterologous PRRSV-challenged pigs. Our results indicated that out of five different vaccine-adjuvant formulations, the combination of NP-KAg and unentrapped M. tb WCL significantly cleared detectable replicating infective PRRSV with a tenfold reduction in viral RNA load in the lungs, associated with substantially reduced gross and microscopic lung pathology. Immunologically, strong humoral (enhanced virus neutralization titers by high avidity antibodies) and cell-mediated immune responses (augmented population of interferon-γ secreting CD4(+) and CD8(+) lymphocytes and reduced secretion of immunosuppressive cytokines) in the lungs were observed. In conclusion, combination of NP-KAg and soluble M. tb WCL elicits broadly cross-protective anti-PRRSV immunity in the pig respiratory system.
format Online
Article
Text
id pubmed-3969340
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39693402014-04-07 An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination Binjawadagi, Basavaraj Dwivedi, Varun Manickam, Cordelia Ouyang, Kang Torrelles, Jordi B Renukaradhya, Gourapura J Int J Nanomedicine Original Research Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and reinfections; moreover, safety of the live virus vaccines is questionable. Though poorly immunogenic, inactivated PRRSV vaccine is safe. The PRRSV infects primarily the lung macrophages. Therefore, we attempted to strengthen the immunogenicity of inactivated/killed PRRSV vaccine antigens (KAg), especially in the pig respiratory system, through: 1) entrapping the KAg in biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP-KAg); 2) coupling the NP-KAg with a potent mucosal adjuvant, whole cell lysate of Mycobacterium tuberculosis (M. tb WCL); and 3) delivering the vaccine formulation twice intranasally to growing pigs. We have previously shown that a single dose of NP-KAg partially cleared the challenged heterologous PRRSV. Recently, we reported that NP-KAg coupled with unentrapped M. tb WCL significantly cleared the viremia of challenged heterologous PRRSV. Since PRRSV is primarily a lung disease, our goal in this study was to investigate lung viral load and various immune correlates of protection at the lung mucosal surfaces and its parenchyma in vaccinated heterologous PRRSV-challenged pigs. Our results indicated that out of five different vaccine-adjuvant formulations, the combination of NP-KAg and unentrapped M. tb WCL significantly cleared detectable replicating infective PRRSV with a tenfold reduction in viral RNA load in the lungs, associated with substantially reduced gross and microscopic lung pathology. Immunologically, strong humoral (enhanced virus neutralization titers by high avidity antibodies) and cell-mediated immune responses (augmented population of interferon-γ secreting CD4(+) and CD8(+) lymphocytes and reduced secretion of immunosuppressive cytokines) in the lungs were observed. In conclusion, combination of NP-KAg and soluble M. tb WCL elicits broadly cross-protective anti-PRRSV immunity in the pig respiratory system. Dove Medical Press 2014-03-24 /pmc/articles/PMC3969340/ /pubmed/24711701 http://dx.doi.org/10.2147/IJN.S59924 Text en © 2014 Binjawadagi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Binjawadagi, Basavaraj
Dwivedi, Varun
Manickam, Cordelia
Ouyang, Kang
Torrelles, Jordi B
Renukaradhya, Gourapura J
An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
title An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
title_full An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
title_fullStr An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
title_full_unstemmed An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
title_short An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
title_sort innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969340/
https://www.ncbi.nlm.nih.gov/pubmed/24711701
http://dx.doi.org/10.2147/IJN.S59924
work_keys_str_mv AT binjawadagibasavaraj aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT dwivedivarun aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT manickamcordelia aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT ouyangkang aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT torrellesjordib aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT renukaradhyagourapuraj aninnovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT binjawadagibasavaraj innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT dwivedivarun innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT manickamcordelia innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT ouyangkang innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT torrellesjordib innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination
AT renukaradhyagourapuraj innovativeapproachtoinducecrossprotectiveimmunityagainstporcinereproductiveandrespiratorysyndromevirusinthelungsofpigsthroughadjuvantednanotechnologybasedvaccination